Crystal form of EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor as well as preparation method and application thereof

The invention relates to a crystal form of an EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor as well as a preparation method and application thereof. Specifically, the invention relates to a crystal form A and a crystal form B of a compound as shown in a formula (I), and a prepara...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	CHU GUOBIAO, WANG MIN, ZHANG ZHIGANG, BAI RUI, HU YANG, WEI KEWEI, ZHAO XIN, WANG LUFENG
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	ACYCLIC OR CARBOCYCLIC COMPOUNDS CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention relates to a crystal form of an EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor as well as a preparation method and application thereof. Specifically, the invention relates to a crystal form A and a crystal form B of a compound as shown in a formula (I), and a preparation method and application of the crystal form A and the crystal form B. The crystal form provided by the invention has good hygroscopicity and stability, and is favorable for being prepared into a medicine for clinically treating diseases related to EGFR exon 20 mutation, especially non-small cell lung cancer. # imgabs0 # 本发明涉及一种EGFR酪氨酸激酶抑制剂的晶型及其制备方法和用途。具体而言，本发明涉及式(I)所示化合物的A晶型和B晶型，以及它们的制备方法和用途。本发明提供的晶型具有良好的引湿性和稳定性，有利于制备成药物用于临床治疗与EGFR外显子20突变相关的疾病特别是非小细胞肺癌。#imgabs0#